|
⚲
|
| Keyboard |
| Scott Requadt | |
|---|---|
| Firm | |
| Address | c/o Talaris Therapeutics, Inc 201 E Jefferson St, Suite 110B Louisville, KY 40202 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Talaris Therapeutics Inc | 021-377389 | Executive Officer | 115.0 M of 115.0 M |
||
| ESSA Pharma Inc | 021-347780 | Director | 36.0 M of 36.0 M |
||
| VBI Vaccines Inc/BC | 021-327445 | Director | 7.0 M of 7.0 M |
||
| AVROBIO Inc | 021-304752 | Director | 60.5 M of 61.0 M |
||
| VBI Vaccines Inc/BC | 021-276702 | Director | 10.6 M of 10.6 M |
||
| AVROBIO Inc | 021-268222 | Director | 7.5 M of 25.0 M |
||
| VBI Vaccines Inc/BC | 021-266313 | Director | 13.6 M of 13.6 M |
||
| ESSA Pharma Inc | 021-260489 | Director | 5.0 M of 5.0 M |
||
| ESSA Pharma Inc | 021-255472 | Director | 15.0 M of 15.0 M |
||
| Clarus Ventures III GP LP | 021-225116 | Executive Officer | of 50.0 M |
||
| TYRX Inc | 021-196569 | Director | 2.0 M of 2.0 M |
||
| TYRX Inc | 021-189287 | Director | 2.0 M of 2.1 M |
||
| TYRX Inc | 021-173235 | Director | 2.5 M of 5.2 M |
||
| TYRX Pharma Inc | 021-151474 | Director | 23.1 M of 25.2 M |
||
| TYRX Pharma Inc | 021-68851 | Director | 11.0 M of 11.0 M |
||
| Clarus Ventures LLC | |||||
| Clarus IV-A LP | 021-286937 | Executive Officer | 789.7 M of 880.0 M |
217.3 M | |
| Clarus IV-B LP | 021-286939 | Executive Officer | 789.7 M of 880.0 M |
139.5 M | |
| Clarus IV-C LP | 021-286940 | Executive Officer | 789.7 M of 880.0 M |
257.5 M | |
| Clarus IV-D LP | 021-286941 | Executive Officer | 789.7 M of 880.0 M |
51.4 M | |
| Clarus Defined Exit I LP | 021-222299 | Executive Officer | 100.0 M of 100.0 M |
63.9 M | |
| Clarus de II LP | 021-224951 | Executive Officer | 40.0 M of 40.0 M |
26.8 M | |